{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:56:21Z","timestamp":1793735781213,"version":"4.6.1"},"reference-count":43,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,11,23]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objective of this study is to examine the temporal trend of antiplatelet prescribing pattern during index hospitalisation discharge in Hong Kong (HK) acute coronary syndrome (ACS) population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>The study is a retrospective observational cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The study retrieved data from electronic health record from Hospital Authority (HA), HK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The study included patients aged 18 years old or above, who were admitted to seven institutions under HA with diagnosis of ACS during 2008\u20132017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The primary outcome was the frequency of antiplatelet therapy prescription at the point of index hospitalisation discharge each year during 2008\u20132017. Association between demographics, baseline comorbidities, procedures and antiplatelet prescription were examined as secondary outcome using multivariate logistic regression model, with commonly used antiplatelet groups selected for comparison.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the included 14\u2009716 patients, 5888 (40.0%) discharged with aspirin alone, 6888 (46.8%) discharged with dual antiplatelet therapy (DAPT) with clopidogrel, and 973 (6.6%) discharged with DAPT with prasugrel\/ticagrelor. Prescribing rate of aspirin alone decreased substantially from 56.8% in 2008 to 27.5% in 2017. Utilisation of DAPT with clopidogrel increased from 33.7% in 2008 to 52.7% in 2017. Use of DAPT with prasugrel\/ticagrelor increased from 0.3% in 2010 to 15.3% in 2017. Compared with those prescribed with DAPT with clopidogrel, male patients (adjusted OR (aOR) 1.34, 95%\u2009CI 1.09 to 1.65), patients with non-ST-elevation myocardial infarction (aOR 2.50, 1.98 to 3.16) or ST-elevation myocardial infarction (aOR 3.26, 2.59 to 4.09), use of glycoprotein IIb\/IIIa (aOR 3.03, 2.48 to 3.68) or undergoing percutaneous coronary intervention (aOR 3.85, 3.24 to 4.58) or coronary artery bypass graft (aOR 6.52, 4.63 to 9.18) during index hospitalisation, concurrent use of histamine-2 receptor antagonists (aOR 1.35, 1.10 to 1.65) or proton pump inhibitors (aOR 3.57, 2.93 to 4.36) during index hospitalisation discharge were more likely to be prescribed with DAPT with prasugrel\/ticagrelor. Patients with older age (aOR 0.97, 0.96 to 0.97), diabetes (aOR 0.68, 0.52 to 0.88), chronic kidney disease (aOR 0.43, 0.22 to 0.85) or concurrent use of oral anticoagulant (aOR 0.16, 0.07 to 0.42) were more likely to received DAPT with clopidogrel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Use of DAPT with prasugrel\/ticagrelor was suboptimal yet improving during 2008\u20132017 in HK patients with ACS. Considering DAPT, predictors for clopidogrel prescription, compared with prasugrel\/ticagrelor, were consistent with identified risk factors of bleeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-042229","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T16:01:39Z","timestamp":1607011299000},"page":"e042229","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Trends of prescribing adherence of antiplatelet agents in Hong Kong patients with acute coronary syndrome: a 10-year retrospective observational cohort study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-2328","authenticated-orcid":false,"given":"Amy SM","family":"Lam","sequence":"first","affiliation":[{"name":"Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan PY","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-8899","authenticated-orcid":false,"given":"Vivian WY","family":"Lee","sequence":"additional","affiliation":[{"name":"Centre for Learning Enhancement And Research, The Chinese University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"2025121401002656000_10.12.e042229.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"2025121401002656000_10.12.e042229.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"2025121401002656000_10.12.e042229.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2411"},{"key":"2025121401002656000_10.12.e042229.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050522"},{"key":"2025121401002656000_10.12.e042229.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.017"},{"key":"2025121401002656000_10.12.e042229.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182742cf6"},{"key":"2025121401002656000_10.12.e042229.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"2025121401002656000_10.12.e042229.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"2025121401002656000_10.12.e042229.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.513"},{"key":"2025121401002656000_10.12.e042229.10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/14017431.2015.1119304","article-title":"Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study","volume":"50","author":"Anger\u00e5s","year":"2016","journal-title":"Scand Cardiovasc J"},{"key":"2025121401002656000_10.12.e042229.11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijcard.2017.04.077","article-title":"The underutilisation of dual antiplatelet therapy in acute coronary syndrome","volume":"240","author":"Anastasius","year":"2017","journal-title":"Int J Cardiol"},{"key":"2025121401002656000_10.12.e042229.12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1074248417724869","article-title":"Temporal trends in the use of antiplatelet therapy in patients with acute coronary syndromes","volume":"23","author":"Esteve-Pastor","year":"2018","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2025121401002656000_10.12.e042229.13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.116.004750"},{"key":"2025121401002656000_10.12.e042229.14","first-page":"189","article-title":"Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study","volume":"3","author":"Claeys","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025121401002656000_10.12.e042229.15","unstructured":"Hospital Authority . Introduction. Available: https:\/\/www3.ha.org.hk\/ntec\/content\/background_e.asp [Accessed 25 Jun 2020]."},{"key":"2025121401002656000_10.12.e042229.16","unstructured":"Department of Health HKSAR . Health facts of Hong Kong 2018 edition, 2018."},{"key":"2025121401002656000_10.12.e042229.17","unstructured":"Hospital Authority . Strategic service framework for coronary heart disease; 2013."},{"key":"2025121401002656000_10.12.e042229.18","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/pds.4208","article-title":"Validity of major osteoporotic fracture diagnosis codes in the clinical data analysis and reporting system in Hong Kong","volume":"26","author":"Sing","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121401002656000_10.12.e042229.19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European heart rhythm association (EHRA), European Society of cardiology Working group on thrombosis, European association of percutaneous cardiovascular interventions (EAPCI), and European association of acute cardiac care (ACCA) endorsed by the heart rhythm Society (HRS), Asia-Pacific heart rhythm Society (APHRS), Latin America heart rhythm Society (LAHRS), and cardiac arrhythmia Society of southern Africa (CASSA)","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"2025121401002656000_10.12.e042229.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61751-7"},{"key":"2025121401002656000_10.12.e042229.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.06.004"},{"key":"2025121401002656000_10.12.e042229.22","first-page":"57","article-title":"Contemporary trends in oral antiplatelet agent use in patients treated with percutaneous coronary intervention for acute coronary syndrome","volume":"23","author":"Kim","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2025121401002656000_10.12.e042229.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00889-5"},{"key":"2025121401002656000_10.12.e042229.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02336-7"},{"key":"2025121401002656000_10.12.e042229.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.07.002"},{"key":"2025121401002656000_10.12.e042229.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.11.025"},{"key":"2025121401002656000_10.12.e042229.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2019-002087"},{"key":"2025121401002656000_10.12.e042229.28","unstructured":"National Medical Products Administration . National essential medicines Lists 2012, 2012."},{"key":"2025121401002656000_10.12.e042229.29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.117.006132"},{"key":"2025121401002656000_10.12.e042229.30","first-page":"535","article-title":"\"Real-World\" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States","volume":"88","author":"Larmore","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"2025121401002656000_10.12.e042229.31","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4070\/kcj.2017.0072","article-title":"The use pattern and clinical impact of new antiplatelet agents including prasugrel and ticagrelor on 30-day outcomes after acute myocardial infarction in Korea: Korean health insurance review and assessment data","volume":"47","author":"Kim","year":"2017","journal-title":"Korean Circ J"},{"key":"2025121401002656000_10.12.e042229.32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10557-018-6839-1","article-title":"Rationale, design, and baseline characteristics of the prospective Japan acute myocardial infarction registry (JAMIR)","volume":"33","author":"Honda","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"2025121401002656000_10.12.e042229.33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.scib.2018.12.020","article-title":"2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"64","author":"Huo","year":"2019","journal-title":"Sci Bull"},{"key":"2025121401002656000_10.12.e042229.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179349","article-title":"Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: a prospective, multi-centre registry","volume":"12","author":"Tscharre","year":"2017","journal-title":"PLoS One"},{"key":"2025121401002656000_10.12.e042229.35","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw284"},{"key":"2025121401002656000_10.12.e042229.36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijcard.2018.09.011","article-title":"Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y12 inhibitors in a large observational study","volume":"274","author":"Choe","year":"2019","journal-title":"Int J Cardiol"},{"key":"2025121401002656000_10.12.e042229.37","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012078","article-title":"Safety and Effectiveness of Contemporary P2Y12 Inhibitors in an East Asian Population With Acute Coronary Syndrome: A Nationwide Population-Based Cohort Study","volume":"8","author":"Yun","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025121401002656000_10.12.e042229.38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1573403X12666160504100025","article-title":"Adherence to cardiac practice guidelines in the management of non-ST-elevation acute coronary syndromes: a systematic literature review","volume":"13","author":"Engel","year":"2017","journal-title":"Curr Cardiol Rev"},{"key":"2025121401002656000_10.12.e042229.39","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1093\/eurheartj\/ehy554","article-title":"Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014","volume":"39","author":"Szummer","year":"2018","journal-title":"Eur Heart J"},{"key":"2025121401002656000_10.12.e042229.40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/1753944717738911","article-title":"Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience","volume":"11","author":"Castini","year":"2017","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2025121401002656000_10.12.e042229.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.09.076"},{"key":"2025121401002656000_10.12.e042229.42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.612812"},{"key":"2025121401002656000_10.12.e042229.43","unstructured":"Hospital Authority . Drug formulary. Available: https:\/\/www.ha.org.hk\/hadf\/en-us\/Updated-HA-Drug-Formulary\/Drug-Formulary.html [Accessed 26 May 2020]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-042229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:00:34Z","timestamp":1765702834000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-042229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,3]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/bmjopen-2020-042229"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-042229","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}